Investors

Development Pipeline

This is the development pipeline as of April 26, 2022

Development Pipeline (As of the latest Announcement of business results)(724 KB)

1. Oncology (OPDIVO)
2. Oncology (Other than OPDIVO)
3. Areas other than Oncology

1. Oncology (OPDIVO)

As of April 26, 2022

Product name or Development code (Generic name)	Mechanism	Target disease	Development stage					Country/ Region	Licensor
Product name or Development code (Generic name)	Mechanism	Target disease	Ⅰ	Ⅱ	Ⅲ	F i l i n g	A p p r o v a l	Country/ Region	Licensor
Opdivo Intravenous Infusion (Nivolumab)	Anti-PD-1 antibody	Melanoma (2nd)						JP・KR・TW	In-house (Co-developed with BMS)
		Melanoma (1st)						JP・KR・TW
		Melanoma (Adjuvant therapy)						JP・KR・TW
		Non-small cell lung cancer (2nd～)						JP・KR・TW
		Non-small cell lung cancer (1st)						JP・KR・TW
		Non-small cell lung cancer (Neoadjuvant therapy)						JP
		Renal cell carcinoma (2nd～)						JP・KR・TW
		Renal cell carcinoma (1st)						JP・KR・TW
		Hodgkin’s lymphoma						JP・KR・TW
		Hodgkin's lymphoma (Pediatric)						JP
		Head and neck cancer						JP・KR・TW
		Gastric cancer (3rd)						JP・KR・TW
		Gastric cancer (1st)						JP・KR・TW
		Malignant pleural mesothelioma (SOC refractory)						JP
		Malignant pleural mesothelioma (1st)						JP・KR・TW
		Colorectal cancer (MSI-High)						JP・KR・TW
		Esophageal cancer (2nd)						JP・KR・TW
		Esophageal cancer (1st)						JP
		Esophageal cancer (1st)						KR・TW
		Esophageal cancer (Adjuvant)						JP・KR・TW
		Urothelial cancer (2nd)						JP
		Urothelial cancer (2nd)						KR・TW
		Urothelial cancer (Adjuvant)						JP・KR・TW
		Cancer of unknown primary						JP
		Hepatocellular carcinoma (Adjuvant therapy)						JP・KR・TW
		Hepatocellular carcinoma (2nd)						TW
		Ovarian cancer						JP・KR・TW
		Bladder cancer						JP・KR・TW
		Prostate cancer						JP・KR・TW
		Pancreatic cancer						JP・KR・TW
		Virus positive/negative solid carcinoma						JP・KR・TW

2. Oncology (Other than OPDIVO)

As of April 26, 2022

Product name or Development code (Generic name)	Mechanism	Target disease	Development stage					Country/ Region	Licensor
Product name or Development code (Generic name)	Mechanism	Target disease	Ⅰ	Ⅱ	Ⅲ	F i l i n g	A p p r o v a l	Country/ Region	Licensor
Yervoy Injection★ (Ipilimumab)	Anti-CTLA-4 antibody	Melanoma						JP・KR・TW	BMS
		Renal cell carcinoma						JP・KR・TW
		Non-small cell lung cancer						JP・KR・TW
		Colorectal cancer (MSI-High)						JP・KR・TW
		Malignant pleural mesothelioma						JP・KR・TW
		Gastric cancer						JP・KR・TW
		Esophageal cancer						JP
		Esophageal cancer						KR・TW
		Urothelial cancer						JP・KR・TW
		Hepatocellular carcinoma						JP・KR・TW
		Virus positive/negative solid carcinoma						JP・KR・TW
Velexbru Tablets (Tirabrutinib Hydrochloride)	Bruton‘s tyrosine kinase (BTK) inhibitor	Primary central nervous system lymphoma						JP・KR・TW	In-house
		Primary central nervous system lymphoma						US
		Primary macroglobulinemia Lymphoplasmacytic lymphoma						JP
Adlumiz Tablets (Anamorelin Hydrochloride)	Ghrelin mimetic	Cancer cachexia						JP	Helsinn
Braftovi Capsules (Encorafenib)	BRAF inhibitor	Melanoma (BRAF-mutation positive)						JP	Pfizer
		Colorectal cancer (BRAF-mutation positive)						JP・KR
		Thyroid cancer (BRAF-mutation positive)						JP
Mektovi Tablets (Binimetinib)	MEK inhibitor	Melanoma (BRAF-mutation positive)						JP	Pfizer
		Colorectal cancer (BRAF-mutation positive)						JP
		Thyroid cancer (BRAF-mutation positive)						JP
Kyprolis for Intravenous Infusion (Carfilzomib)	Proteasome inhibitor	Multiple myeloma						JP	Amgen
ONO-7913 (Magrolimab)	Anti-CD47 antibody	TP53-mutant Acute myeloid leukemia						JP	Gilead
		Acute myeloid leukemia						KR・TW
		Solid tumor						JP
		Myelodysplastic syndrome						JP
		Pancreatic cancer★						JP
		Colorectal cancer★						JP
ONO-4686 ★	Anti-TIGIT antibody	Solid tumor						JP	BMS
ONO-4482★ (Relatlimab)	Anti-LAG-3 antibody	Melanoma						JP	BMS
ONO-7475	Axl/Mer inhibitor	Solid tumor★						JP	In-house
		EGFR-mutated non-small cell lung cancer						JP
		Acute leukemia						US
ONO-4578	PG receptor (EP4) antagonist	Solid tumor・Gastric cancer★						JP	In-house
		Colorectal cancer★						JP
		Pancreatic cancer★						JP
		Non-small cell lung cancer★						JP
		Hormone receptor-positive, HER2-negative breast cancer						JP
ONO-7119★ (Atamparib)	PARP7 inhibitor	Solid tumor						JP	Ribon
ONO-7122★	TGF-β inhibitor	Solid tumor						JP	BMS
ONO-7914★	STING agonist	Solid tumor						JP	In-house
ONO-4685	PD-1×CD3 bispecific antibody	T-cell lymphoma						US	In-house

★Combination with Opdivo.

3. Areas other than Oncology

As of April 26, 2022

Product name or Development code (Generic name)	Mechanism	Target disease	Development stage					Country/ Region	Licensor
Product name or Development code (Generic name)	Mechanism	Target disease	Ⅰ	Ⅱ	Ⅲ	F i l i n g	A p p r o v a l	Country/ Region	Licensor
Coralan Tablets (Ivabradine Hydrochloride)	HCN channel blocker	Chronic heart failure						JP	Servier
Ongentys Tablets (Opicapone)	Long acting COMT inhibitor	Parkinson’s disease						JP	Bial
Onoact for Intravenous Infusion (Landiolol Hydrochloride)	Short-active selective β1 blocker	Tachyarrhythmia associated with sepsis						JP	In-house
Onoact for Intravenous Infusion (Landiolol Hydrochloride)	Short-active selective β1 blocker	Tachyarrhythmia in low cardiac function (Pediatric)						JP	In-house
Orencia SC (Abatacept )	T-cell activation inhibitor	Rheumatoid arthritis (Prevention of structural damage of joints)						JP	BMS
Joyclu Intra-articular Injection (Diclofenac Etalhyaluronate Sodium)	Hyaluronic acid-NSAID	Osteoarthritis (hip,knee)						JP	Seikagaku
ONO-2017 (Cenobamate)	Inhibition of voltage-gated sodium currents/positive allosteric modulator of GABA_A ion channel	Primary generalized tonic-clonic seizures						JP	SKBP
ONO-2017 (Cenobamate)		Partial-onset seizures						JP	SKBP
Velexbru Tablets (Tirabrutinib Hydrochloride)	Bruton's tyrosine kinase (BTK) inhibitor	Pemphigus						JP	In-house
Velexbru Tablets (Tirabrutinib Hydrochloride)	Bruton's tyrosine kinase (BTK) inhibitor	Generalized scleroderma						JP	In-house
ONO-2910	Enhancement of Schwann cell differentiation	Diabetic polyneuropathy						JP	In-house
ONO-4685	PD-1×CD3 bispecific antibody	Autoimmune disease						JP・EU	In-house
ONO-2808	S1P5 receptor agonist	Neurodegenerative disease						JP・EU	In-house
ONO-7684	FXIa inhibitor	Thrombosis						EU	In-house
ONO-2909	PG receptor (DP1) antagonist	Narcolepsy						JP	In-house